Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis

Histopathology

Volumn 60, Issue 6 B, 2012, Pages

  Geyer, Felipe C ^a,l   Lacroix Triki, Magali ^b   Colombo, Pierre Emmanuel ^c   Patani, Neill ^a   Gauthier, Arnaud ^d   Natrajan, Rachael ^a   Lambros, Maryou B K ^a   Khalifeh, Ibrahim ^e   Albarracin, Constance ^f   Orru, Sandra ^g   Marchiò, Caterina ^h   Sapino, Anna ^h   Mackay, Alan ^a   Weigelt, Britta ⁱ   Schmitt, Fernando C ^j   Wesseling, Jelle ^k   Sneige, Nour ^d   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE VAL D AURELLE   (France)

^d INSTITUT CURIE   (France)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g Ospedale Oncologico A Businco   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^j University of Porto   (Portugal)

^k ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^l HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

more..

Author keywords

Basal like; Comparative genomic hybridization; Immunohistochemistry; Invasive ductal carcinoma; Microglandular adenosis; Triple negative

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; PROTEIN S 100;

ARTICLE; BREAST FIBROADENOMA; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MICRODISSECTION; MICROGLANDULAR ADENOSIS; PRIORITY JOURNAL; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860335910     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04207.x     Document Type: Article

References (52)

1. Rosen P ed. Rosen's Breast pathology, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
2. Geyer FC, Kushner YB, Lambros MB et al. Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. Histopathology 2009; 55; 732-743.
3. Khalifeh IM, Albarracin C, Diaz LK et al. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in-situ and invasive carcinoma. Am. J. Surg. Pathol. 2008; 32; 544-552.
4. Koenig C, Dadmanesh F, Bratthauer GL, Tavassoli FA. Carcinoma arising in microglandular adenosis: an immunohistochemical analysis of 20 intraepithelial and invasive neoplasms. Int. J. Surg. Pathol. 2000; 8; 303-315.
5. Rosen PP. Microglandular adenosis. A benign lesion simulating invasive mammary carcinoma. Am. J. Surg. Pathol. 1983; 7; 137-144.
6. Rosenblum MK, Purrazzella R, Rosen PP. Is microglandular adenosis a precancerous disease? A study of carcinoma arising therein. Am. J. Surg. Pathol. 1986; 10; 237-245.
7. Shin SJ, Simpson PT, Da Silva L et al. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. Am. J. Surg. Pathol. 2009; 33; 496-504.
8. James BA, Cranor ML, Rosen PP. Carcinoma of the breast arising in microglandular adenosis. Am. J. Clin. Pathol. 1993; 100; 507-513.
9. Arriola E, Lambros MB, Jones C et al. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab. Invest. 2007; 87; 75-83.
10. Lacroix-Triki M, Suarez PH, MacKay A et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J. Pathol. 2010; 222; 282-298.
11. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010; 28; 2784-2795.
12. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL. Resolving the resolution of array CGH. Genomics 2007; 89; 647-653.
13. Gunnarsson R, Staaf J, Jansson M et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosom. Cancer 2008; 47; 697-711.
14. Tan DS, Lambros MB, Natrajan R, Reis-Filho JS. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab. Invest. 2007; 87; 737-754.
15. Natrajan R, Lambros MB, Rodriguez-Pinilla SM et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 2009; 15; 2711-2722.
16. Wetterskog D, Lopez-Garcia MA, Lambros MB et al. Breast adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J. Pathol. 2012; 226; 84-96.
17. Azoulay S, Lae M, Freneaux P et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod. Pathol. 2005; 18; 1623-1631.
18. Lae M, Freneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod. Pathol. 2009; 22; 291-298.
19. Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006; 49; 10-21.
20. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol. Oncol. 2010; 4; 192-208.
21. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008; 216; 141-150.
22. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res. Treat. 2009; 117; 273-280.
23. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat. Rev. Clin. Oncol. 2009; 6; 718-730.
24. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 2010; 363; 1938-1948.
25. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
26. Shiu KK, Natrajan R, Geyer FC, Ashworth A, Reis-Filho JS. DNA amplifications in breast cancer: genotypic-phenotypic correlations. Future Oncol. 2010; 6; 967-984.
27. Turner N, Lambros MB, Horlings HM et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29; 2013-2023.
28. Adelaide J, Finetti P, Bekhouche I et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007; 67; 11565-11575.
29. Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res. 2009; 15; 441-451.
30. Natrajan R, Weigelt B, Mackay A et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res. Treat. 2010; 121; 575-589.
31. Chin K, DeVries S, Fridlyand J et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10; 529-541.
32. Han W, Jung EM, Cho J et al. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosom. Cancer 2008; 47; 490-499.
33. Natrajan R, Lambros MB, Geyer FC et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosom. Cancer 2009; 48; 351-365.
34. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010; 57; 171-192.
35. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 2010; 220; 263-280.
36. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am. J. Surg. Pathol. 2007; 31; 417-426.
37. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J. Pathol. 2011; 223; 307-317.
38. Hungermann D, Schmidt H, Natrajan R et al. Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. J. Pathol. 2011; 224; 517-528.
39. Reis-Filho JS, Drury S, Lambros MB et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat. Genet. 2008; 40; 809-810.
40. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
41. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
42. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003; 100; 8418-8423.
43. Weigelt B, Mackay A, A'Hern R et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 11; 339-349.
44. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat. Rev. Clin. Oncol. 2012; 9; 58-64.
45. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 2007; 7; 791-799.
46. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res. 2011; 13; 212.
47. Badve S, Dabbs DJ, Schnitt SJ et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011; 24; 157-167.
48. Lim E, Vaillant F, Wu D et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009; 15; 907-913.
49. Molyneux G, Geyer FC, Magnay FA et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010; 7; 403-417.
50. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011; 145; 30-38.
51. Aparicio SA, Huntsman DG. Does massively parallel DNA resequencing signify the end of histopathology as we know it? J. Pathol. 2010; 220; 307-315.
52. Natrajan R, Reis-Filho JS. Next-generation sequencing applied to molecular diagnostics. Exp. Rev. Mol. Diagn. 2011; 11; 425-444.